Taken together, these observations suggest that the IgA response we observed in the setting of breakthrough infection is a de novo local immune response rather than an anamnestic response and that different approaches (e.g., use of adjuvants, different routes of administration) will be required to improve mucosal immunogenicity for intramuscularly injected vaccines.51 Here, CD79A is linked to infection.